Literature DB >> 23997074

Cardiac transplant in a family pedigree of hypertrophic cardiomyopathy secondary to a mutation in the AMP gene.

Rebecca Sally Schofield1, Katherine McGarry, Claire Louise Murphy, Kevin O'Hare.   

Abstract

The phenotype of this unique condition comprises left ventricular hypertrophy (LVH), accessory pathways, atrial arrhythmia and premature failure of the atrioventricular node. At age 11, his ECG showed marked voltage criteria for LVH but his echocardiography was negative. He declined further screening but was reassessed at 21 years of age. By this time he had developed significant LVH. He had an implantable cardioventer defibrillator (ICD) in 2001. He developed atrial flutter and fibrillation which was initially treated with medical therapy and then radiofrequency ablation.Unfortunately, his condition deteriorated. He was New York Heart Association (NYHA) class 3-4 for most of 2011 and spent the latter part of the year and most of 2012 as an in-patient. An attempt to upgrade his ICD to a cardiac resynchronisation therapy-defibrillator was unsuccessful.In March 2012 he was placed on the transplant waiting list. He received an organ in June. He is now NHYA class 1 and has returned to work part-time.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23997074      PMCID: PMC3762149          DOI: 10.1136/bcr-2013-009929

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  2 in total

1.  Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy.

Authors:  Michael Arad; D Woodrow Benson; Antonio R Perez-Atayde; William J McKenna; Elizabeth A Sparks; Ronald J Kanter; Kate McGarry; J G Seidman; Christine E Seidman
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

2.  Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history.

Authors:  Ross T Murphy; Jens Mogensen; Kate McGarry; Ajay Bahl; Alison Evans; Eyman Osman; Petros Syrris; Grainne Gorman; Michael Farrell; Janice L Holton; Michael G Hanna; Sian Hughes; Perry M Elliott; Calum A Macrae; William J McKenna
Journal:  J Am Coll Cardiol       Date:  2005-03-15       Impact factor: 24.094

  2 in total
  1 in total

Review 1.  Targeting the energy guardian AMPK: another avenue for treating cardiomyopathy?

Authors:  Tian Li; Shuai Jiang; Zhi Yang; Zhiqiang Ma; Wei Yi; Dongjin Wang; Yang Yang
Journal:  Cell Mol Life Sci       Date:  2016-11-04       Impact factor: 9.261

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.